BRAF Fusion - Another Mechanism of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

被引：2

作者：

Mitsudomi, Tetsuya ^{[1
]}

机构：

[1] Kindai Univ, Dept Surg, Fac Med, Div Thorac Surg, 377-2 Ohno Higashi, Osaka, Osaka 5898511, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 05期

关键词：

CANCER; TUMORS;

D O I：

10.1016/j.jtho.2019.03.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：764 / 765

页数：2

共 9 条

[1] MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Engelman, Jeffrey A.
Zejnullahu, Kreshnik
Mitsudomi, Tetsuya
Song, Youngchul
Hyland, Courtney
Park, Joon Oh
Lindeman, Neal
Gale, Christopher-Michael
Zhao, Xiaojun
Christensen, James
Kosaka, Takayuki
Holmes, Alison J.
Rogers, Andrew M.
Cappuzzo, Federico
Mok, Tony
Lee, Charles
Johnson, Bruce E.
Cantley, Lewis C.
Janne, Pasi A.
[J]. SCIENCE, 2007, 316 (5827) : 1039 - 1043
[2] Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
Holderfield, Matthew
Deuker, Marian M.
McCormick, Frank
McMahon, Martin
[J]. NATURE REVIEWS CANCER, 2014, 14 (07) : 455 - 467
[3] Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion
Menzies, Alexander M.
Yeh, Iwei
Botton, Thomas
Bastian, Boris C.
Scolyer, Richard A.
Long, Georgina V.
[J]. PIGMENT CELL & MELANOMA RESEARCH, 2015, 28 (05) : 607 - 610
[4] The distribution of BRAF gene fusions in solid tumors and response to targeted therapy
Ross, Jeffrey S.
Wang, Kai
Chmielecki, Juliann
Gay, Laurie
Johnson, Adrienne
Chudnovsky, Jacob
Yelensky, Roman
Lipson, Doron
Ali, Siraj M.
Elvin, Julia A.
Vergilio, Jo-Anne
Roels, Steven
Miller, Vincent A.
Nakamura, Brooke N.
Gray, Adam
Wong, Michael K.
Stephens, Philip J.
[J]. INTERNATIONAL JOURNAL OF CANCER, 2016, 138 (04) : 881 - 890
[5] Understanding and targeting resistance mechanisms in NSCLC
Rotow, Julia
Bivona, Trever G.
[J]. NATURE REVIEWS CANCER, 2017, 17 (11) : 637 - 658
[6] Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors
Schrock, Alexa B.
Zhu, Viola W.
Hsieh, Wen-Son
Madison, Russell
Creelan, Benjamin
Silberberg, Jeffrey
Costin, Dan
Bharne, Anjali
Bonta, Ioana
Bosemani, Thangavijayan
Nikolinakos, Petros
Ross, Jeffrey S.
Miller, Vincent A.
Ali, Siraj M.
Klempner, Samuel J.
Ou, Sai-Hong Ignatius
[J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : 1312 - 1323
[7] BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications , and Concurrent Alterations
Sheikine, Yuri
Pavlick, Dean
Klempner, Samuel J.
Trabucco, Sally E.
Chung, Jon H.
Rosenzweig, Mark
Wang, Kai
Velcheti, Vamsidhar
Frampton, Garrett M.
Peled, Nir
Murray, Molly
Chae, Young Kwang
Albacker, Lee A.
Gay, Laurie
Husain, Hatim
Suh, James H.
Millis, Sherri Z.
Reddy, Venkataprasanth P.
Elvin, Julia A.
Hartmaier, Ryan J.
Dowlati, Afshin
Stephens, Phil
Ross, Jeffrey S.
Bivona, Trever G.
Miller, Vincent A.
Ganesan, Shridar
Schrock, Alexa B.
Ou, Sai-Hong Ignatius
Ali, Siraj M.
[J]. JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 15
[8] Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers
Vojnic, Morana
Kubota, Daisuke
Kurzatkowski, Christopher
Offin, Michael
Suzawa, Ken
Benayed, Ryma
Schoenfeld, Adam J.
Plodkowski, Andrew J.
Poirier, John T.
Rudin, Charles M.
Kris, Mark G.
Rosen, Neal X.
Yu, Helena A.
Riely, Gregory J.
Arcila, Maria E.
Somwar, Romel
Ladanyi, Marc
[J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (05) : 802 - 815
[9] Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
Yao, Zhan
Yaeger, Rona
Rodrik-Outmezguine, Vanessa S.
Tao, Anthony
Torres, Neilawattie M.
Chang, Matthew T.
Drosten, Matthias
Zhao, Huiyong
Cecchi, Fabiola
Hembrough, Todd
Michels, Judith
Baumert, Herve
Miles, Linde
Campbell, Naomi M.
de Stanchina, Elisa
Solit, David B.
Barbacid, Mariano
Taylor, Barry S.
Rosen, Neal
[J]. NATURE, 2017, 548 (7666) : 234 - +

← 1 →